Novel B-cell maturation antigen-directed immunotherapies are ready to take their place as the new standard for treatment of advanced multiple myeloma, according to a panel at NCCN 2022 Annual Congress: Hematologic Malignancies.
“Immunotherapy is here for multiple myeloma,” Christopher R. D’Angelo, MD, assistant professor in the division of hematology and oncology at University of Nebraska Medical Center, told the audience.
D’Angelo joined two other multiple myeloma specialists who presented case studies and gave the audience recommendations on how to incorporate newer
